Asia
With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.
Shares of Chinese pharmaceutical and medical device company WuXi AppTec were a hot commodity Tuesday as the company made its debut on the Shanghai Stock Exchange. Another Chinese company, Ascletis Pharma, also chose a new stock listing.
Shares of Adocia are up nearly 30 percent this morning after the company announced it granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals.
China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies. Last week BioSpace reported that China expects to see exponential industry growth by 2022 and today Eli Lilly and Company added to that growth through a partnership with China’s National Center for Cardiovascular Diseases.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.
Recently, Dr. Wang discussed China life science with partneringNEWS, a publication of EBD Group. ChinaBio and EBD will hold the tenth iteration of the ChinaBio Partnering Forum in Suzhou, China on April 25-26, 2018.
PRESS RELEASES